Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IoM monographs

This article was originally published in The Tan Sheet

Executive Summary

Draft prototype safety monographs on melatonin, chromium picolinate, glucosamine and saw palmetto to be subject of public meeting at National Academies in Washington, D.C. Jan. 29. Drafts currently do not offer conclusions about ingredients' safety; modification is expected following stakeholder input. Developed by the Committee on the Framework for Evaluating the Safety of Dietary Supplements, monographs on melatonin, glucosamine and saw palmetto were posted on the 1Food & Nutrition Board Web site Jan. 15; chromium picolinate monograph scheduled to be available Jan. 22. Monographs are part of safety evaluation process outlined last summer (2"The Tan Sheet" July 29, 2002, p. 4)...

You may also be interested in...

Three-Step Supplement Safety Review Model Proposed by IoM

Outside review organizations could play a key role in preparing dietary supplement safety monographs as part of the Institute of Medicine's Proposed Framework for Evaluating the Safety of Dietary Supplements

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts